Small Molecule Wnt Pathway Inhibitor (SM04755) as a Potential Topical Psoriasis Treatment
April 2017
in “
Journal of Investigative Dermatology
”
Wnt signaling pathway SM04755 pro-inflammatory cytokine monocytes PBMCs cytokine-induced keratinocyte proliferation fibrosis markers human dermal fibroblasts clobetasol T cell activation cytokine secretion Wnt pathway small-molecule inhibitor inflammation white blood cells peripheral blood mononuclear cells skin cell growth skin fibrosis skin cells steroid cream immune cells immune response

TLDR SM04755 may be an effective topical treatment for psoriasis.
In a study from 2017, SM04755, a small-molecule inhibitor of the Wnt signaling pathway, showed promise as a topical treatment for psoriasis. It effectively inhibited Wnt signaling, reduced pro-inflammatory cytokine secretion in monocytes and PBMCs, and curbed cytokine-induced keratinocyte proliferation. Additionally, it decreased fibrosis markers in human dermal fibroblasts. In a mouse model of psoriasis, SM04755 improved skin health, reduced skin and ear thickness, and decreased spleen weight, all with statistical significance compared to a control. While the positive control, clobetasol, reduced skin thickness more effectively, it also caused thinning below normal levels, suggesting an adverse effect. SM04755 also inhibited T cell activation and cytokine secretion ex vivo, further supporting its potential as a psoriasis treatment.